BMS 184476

Drug Profile

BMS 184476

Latest Information Update: 16 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adenocarcinoma; Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 03 May 2004 A study has been added to the Cancer therapeutic trials section
  • 02 Sep 2003 Phase-II clinical trials in Ovarian cancer in United Kingdom (IV-infusion)
  • 22 Jul 2002 A clinical study in patients with malignant melanoma has been added to the Cancer therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top